secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001558370-25-007259
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent Q1 cash $205.5M, net loss $64.4M; Phase 3 enrollment completed for firmonertinib
--------------------------------------------------------------------------------

- Cash $205.5M as of March 31, 2025; net loss $64.4M (vs $17.4M YoY) due to $40M upfront payment to Lepu for ARR-217.
- Completed enrollment in global pivotal Phase 3 FURVENT study for firmonertinib in first-line NSCLC EGFR exon20 insertion mutations.
- Plans to provide update on firmonertinib in EGFR PACC mutant NSCLC in Q2 2025; topline Phase 3 data expected in 2025.
- First IND for ARR-217 (CDH17 ADC) submitted in China; initial focus on colorectal, pancreatic, and other GI cancers.
- Appointed Merdad Parsey, former Gilead CMO, to Board of Directors in April 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/0001558370-25-007259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer